Maternal Serum Screening

Pricing ARUP Client Services (800) 522-2787
Genetic Counselors Danielle LaGrave, MS, LCGC

Danielle LaGrave, M.S., L.C.G.C.,Danielle LaGrave, MS, LCGC, Genetic Counselor
Danielle LaGrave is a genetic counselor with ARUP's Maternal Serum Screening program and Cytogenetics Department. She is certified by the American Board of Genetic Counseling, is licensed by the state of Utah, and is a member of the National Society of Genetic Counselors and the American Society of Human Genetics. Ms. LaGrave received her MS in genetic counseling from California State University, Northridge, and has been a practicing genetic counselor since 1996.

(800) 242-2787 x2020
Amanda Openshaw, MS, LGC

Amanda Openshaw, M.S., L.G.C., Genetic Counselor

Amanda Openshaw, MS, LGC, Genetic Counselor
Amanda Openshaw is a genetic counselor with ARUP's Maternal Serum Screening Program and Molecular Genetics Department. She has board eligibility by the American Board of Genetic Counseling, is licensed by the state of Utah, and is a member of the National Society of Genetic Counselors. Ms. Openshaw received her MS in genetic counseling from the University of Michigan.

(800) 242-2787 x2141
Patti Franckowiak, MS, LGC

Patti Franckowiak, M.S., L.C.G.

Patti Franckowiak, MS, LCG, Genetic Counselor
Patti Franckowiak is a genetic counselor with ARUP's Molecular Genetics Department and Maternal Serum screening Program. She has board eligibility by the American Board of Genetic Counseling, is licensed by the state of Utah, and is a member of the National Society of Genetic Counselors. Ms. Franckowiak received her MS in genetic counseling from the University of Michigan.

(800) 242-2787 x3439
  (STAT recalculations, interpretation, or ordering instructions)
Laboratory Director Edward R. Ashwood, MD

Edward R. Ashwood, MD
Director of Laboratories
Medical Director, Central Specimen Processing Laboratory
Medical Director, Serological, Hepatitis, and Retrovirus Laboratory
Medical Director, Special Chemistry Laboratory

Dr. Ashwood is a senior vice president and director of laboratories at ARUP, the medical director of Specimen Processing Laboratory and Serological, Hepatitis, and Retrovirus Laboratory, and acting medical director of the Special Chemistry Laboratory. He is also a professor of pathology at the University of Utah School of Medicine. He received his MD from the University of Colorado and is board certified in clinical and chemical pathology. His research interests include medical informatics. Dr. Ashwood coedits the Tietz Textbook of Clinical Chemistry.

 

 

Patient Information Downloads
Maternal Serum Screening: Choices for Expectant Parents
Maternal Serum Triple Screen
Triple Estudio del Suero Maternal
Maternal Serum Quadruple Screen
Cuadruple de Suero Maternal
Maternal Serum Screening: The Integrated Test
Maternal Serum Screening: First Trimester Screening
Prueba de Suero Materno en el Primer Trimestre
First-Trimester Screening ARUP Technical Bulletins
*Sonographer providing NT measurement must be certified by FASTER trial, NTQR (SMFM), or FMF. Please contact genetic counselor prior to sending first sample to ensure acceptability.  
0081150 * First Trimester Screen PAPP-A, hCG, and nuchal translucency (NT) measurement
Combined First- and Second-Trimester Screening
*Sonographer providing NT measurement must be certified by FASTER trial, NTQR (SMFM), or FMF. Please contact genetic counselor prior to sending first sample to ensure acceptability.
0081062 * Integrated Screen, Specimen #1 PAPP-A, nuchal translucency (NT) measurement; risk result provided after specimen #2.
Serum-only integrated testing is available if NT measurement cannot be obtained or if sonographer is not NT certified.
0081064 Integrated Screen, Specimen #2 Alpha Fetoprotein, hCG, Estriol, and Inhibin A; combined risk result for specimens #1 and #2
0081293 * Sequential Screen, Specimen #1 PAPP-A, nuchal translucency (NT) measurement
Interpretation—Abnormal: Pregnancy is at ≥1 in 25 risk of Down syndrome or ≥ 1 in 100 for trisomy 18; diagnostic testing and genetic counseling should be offered. Negative: Down syndrome risk does not exceed 1 in 25; trisomy 18 risk does not exceed 1 in 100; specimen #2 should be drawn.
0081294 Sequential Screen, Specimen #2 Alpha Fetoprotein, hCG, Estriol, and Inhibin A; results combined with specimen #1 to provide final risk.  
Second-Trimester Screening
0080108 Triple Screen Alpha Fetoprotein, hCG, and Estriol 
0080269 Quad Screen Alpha Fetoprotein, hCG, Estriol, and Inhibin A
0080434 Alpha Fetoprotein Only AFP only; after first trimester screening or CVS
0080427 AFP (Amniotic Fluid) with Reflex to Acetylcholinesterase
 
All ARUP Sites:        www.aruplab.com     ·     www.arupconsult.com     ·     www.arup.utah.edu     ·     www.childx.org     ·     www.utahblood.org